α-synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease

Human Molecular Genetics

Volumn 21, Issue 14, 2012, Pages 3173-3192

  Lastres Becker, Isabel ^a   Ulusoy, Ayse ^b,c   Innamorato, Nadia G ^a   Sahin, Gurdal ^b   Rábano, Alberto ^d   Kirik, Deniz ^b   Cuadrado, Antonio ^a  

^a AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^b LUND UNIVERSITY   (Sweden)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^d Instituto de Salud Carlos III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; HEME OXYGENASE 1; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE QUINONE OXIDOREDUCTASE 1; PARVOVIRUS VECTOR; PROTEASOME; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BRAIN TISSUE; CONTROLLED STUDY; DEGENERATION; DENDRITE; DISEASE COURSE; DOPAMINERGIC NERVE CELL; GLIOSIS; LEWY BODY; MESENCEPHALON; MICROGLIA; MOUSE; NERVE CELL NECROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARKINSON DISEASE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION;

ALPHA-SYNUCLEIN; ANIMALS; CELL DEATH; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HEME OXYGENASE-1; HUMANS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEURONS; NF-E2-RELATED FACTOR 2; PARKINSON DISEASE;

ANIMALIA; MUS;

EID: 84864023667     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/dds143     Document Type: Article

References (68)

1. Braak, H., Del Tredici, K., Rub, U., de Vos, R.A., Jansen Steur, E.N. and Braak, E. (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging, 24, 197-211.
2. Lees, A.J., Hardy, J. and Revesz, T. (2009) Parkinson's disease. Lancet, 373, 2055-2066.
3. Hardy, J. (2010) Genetic analysis of pathways to Parkinson disease. Neuron, 68, 201-206.
4. Lotharius, J. and Brundin, P. (2002) Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. Hum. Mol. Genet., 11, 2395-2407.
5. Outeiro, T.F., Klucken, J., Bercury, K., Tetzlaff, J., Putcha, P., Oliveira, L.M., Quintas, A., McLean, P.J. and Hyman, B.T. (2009) Dopamine-induced conformational changes in alpha-synuclein. PLoS ONE, 4, e6906.
6. Bisaglia, M., Tosatto, L., Munari, F., Tessari, I., de Laureto, P.P., Mammi, S. and Bubacco, L. (2010) Dopamine quinones interact with alphasynuclein to form unstructured adducts. Biochem. Biophys. Res. Commun., 394, 424-428.
7. Zhang, W., Wang, T., Pei, Z., Miller, D.S., Wu, X., Block, M.L., Wilson, B., Zhou, Y., Hong, J.S. and Zhang, J. (2005) Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J., 19, 533-542.
8. Lee, J.K., Tran, T. and Tansey, M.G. (2009) Neuroinflammation in Parkinson's disease. J. Neuroimmune Pharmacol., 4, 419-429.
9. Halliday, G.M. and Stevens, C.H. (2011) Glia: initiators and progressors of pathology in Parkinson's disease. Mov. Disord., 26, 6-17.
10. Austin, S.A., Floden, A.M., Murphy, E.J. and Combs, C.K. (2006) Alpha-synuclein expression modulates microglial activation phenotype. J. Neurosci., 26, 10558-10563.
11. Meredith, G.E., Sonsalla, P.K. and Chesselet, M.F. (2008) Animal models of Parkinson's disease progression. Acta Neuropathol., 115, 385-398.
12. Eslamboli, A. (2005) Assessment of GDNF in primate models of Parkinson's disease: comparison with human studies. Rev. Neurosci., 16, 303-310.
13. Georgievska, B., Kirik, D., Rosenblad, C., Lundberg, C. and Bjorklund, A. (2002) Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport, 13, 75-82.
14. Kirik, D., Georgievska, B., Rosenblad, C. and Bjorklund, A. (2001) Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease. Eur. J. Neurosci., 13, 1589-1599.
15. Decressac, M., Ulusoy, A., Mattsson, B., Georgievska, B., Romero-Ramos, M., Kirik, D. and Bjorklund, A. (2011) GDNF fails to exert neuroprotection in a rat {alpha}-synuclein model of Parkinson's disease. Brain, 134, 2302-2311.
16. Lo Bianco, C., Deglon, N., Pralong, W. and Aebischer, P. (2004) Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease. Neurobiol. Dis., 17, 283-289.
17. Kirik, D., Georgievska, B., Burger, C., Winkler, C., Muzyczka, N., Mandel, R.J. and Bjorklund, A. (2002) Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-DOPA using rAAV-mediated gene transfer. Proc. Natl Acad. Sci. USA, 99, 4708-4713.
18. Ulusoy, A., Decressac, M., Kirik, D. and Bjorklund, A. (2010) Viral vector-mediated overexpression of alpha-synuclein as a progressive model of Parkinson's disease. Prog. Brain. Res., 184, 89-111.
19. Kirik, D., Annett, L.E., Burger, C., Muzyczka, N., Mandel, R.J. and Bjorklund, A. (2003) Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc. Natl Acad. Sci. USA, 100, 2884-2889.
20. Braak, H. and Braak, E. (2000) Pathoanatomy of Parkinson's disease. J. Neurol., 247 (Suppl 2), II3-II10.
21. Galvin, J.E., Uryu, K., Lee, V.M. and Trojanowski, J.Q. (1999) Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc. Natl Acad. Sci. USA, 96, 13450-13455.
22. St Martin, J.L., Klucken, J., Outeiro, T.F., Nguyen, P., Keller-McGandy, C., Cantuti-Castelvetri, I., Grammatopoulos, T.N., Standaert, D.G., Hyman, B.T. and McLean, P.J. (2007) Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse Substantia nigra. J. Neurochem., 100, 1449-1457.
23. Innamorato, N.G., Rojo, A.I., Garcia-Yague, A.J., Yamamoto, M., de Ceballos, M.L. and Cuadrado, A. (2008) The transcription factor Nrf2 is a therapeutic target against brain inflammation. J. Immunol., 181, 680-689.
24. Rojo, A.I., Innamorato, N.G., Martin-Moreno, A.M., De Ceballos, M.L., Yamamoto, M. and Cuadrado, A. (2010) Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia, 58, 588-598.
25. Jazwa, A., Rojo, A.I., Innamorato, N.G., Hesse, M., Fernandez-Ruiz, J. and Cuadrado, A. (2011) Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. Antioxid. Redox Signal, 14, 2347-2360.
26. Barone, M.C., Sykiotis, G.P. and Bohmann, D. (2011) Genetic activation of Nrf2 signaling is sufficient to ameliorate neurodegenerative phenotypes in a Drosophila model of Parkinson's disease. Dis. Model. Mech., 4, 701-707.
27. Innamorato, N.G., Lastres-Becker, I. and Cuadrado, A. (2009) Role of microglial redox balance in modulation of neuroinflammation. Curr. Opin. Neurol., 22, 308-314.
28. Kwak, M.K., Cho, J.M., Huang, B., Shin, S. and Kensler, T.W. (2007) Role of increased expression of the proteasome in the protective effects of sulforaphane against hydrogen peroxide-mediated cytotoxicity in murine neuroblastoma cells. Free Radic. Biol. Med., 43, 809-817.
29. Pickering, A.M., Linder, R.A., Zhang, H., Forman, H.J. and Davies, K.J. (2012) Nrf2 dependent induction of proteasome and Pa28alphabeta regulator is required for adaptation to oxidative stress. J. Biol. Chem., 287, 10021-10031.
30. Ramsey, C.P., Glass, C.A., Montgomery, M.B., Lindl, K.A., Ritson, G.P., Chia, L.A., Hamilton, R.L., Chu, C.T. and Jordan-Sciutto, K.L. (2007) Expression of Nrf2 in neurodegenerative diseases. J. Neuropathol. Exp. Neurol., 66, 75-85.
31. von Otter, M., Landgren, S., Nilsson, S., Celojevic, D., Bergstrom, P., Hakansson, A., Nissbrandt, H., Drozdzik, M., Bialecka, M., Kurzawski, M. et al. (2010) Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease. BMC Med. Genet., 11, 36.
32. von Otter, M., Landgren, S., Nilsson, S., Zetterberg, M., Celojevic, D., Bergstrom, P., Minthon, L., Bogdanovic, N., Andreasen, N., Gustafson, D.R. et al. (2010) Nrf2-encoding NFE2L2 haplotypes influence disease progression but not risk in Alzheimer's disease and age-related cataract. Mech. Ageing Dev., 131, 105-110.
33. Suh, J.H., Shenvi, S.V., Dixon, B.M., Liu, H., Jaiswal, A.K., Liu, R.M. and Hagen, T.M. (2004) Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid. Proc. Natl Acad. Sci. USA, 101, 3381-3386.
34. Maingay, M., Romero-Ramos, M., Carta, M. and Kirik, D. (2006) Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression. Neurobiol. Dis., 23, 522-532.
35. Kirik, D. and Bjorklund, A. (2003) Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors. Trends Neurosci., 26, 386-392.
36. Kirik, D., Rosenblad, C., Burger, C., Lundberg, C., Johansen, T.E., Muzyczka, N., Mandel, R.J. and Bjorklund, A. (2002) Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci., 22, 2780-2791.
37. Grealish, S., Mattsson, B., Draxler, P. and Bjorklund, A. (2010) Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease. Eur. J. Neurosci., 31, 2266-2278.
38. Lee, J., Zhu, W.M., Stanic, D., Finkelstein, D.I., Horne, M.H., Henderson, J., Lawrence, A.J., O'Connor, L., Tomas, D., Drago, J. et al. (2008) Sprouting of dopamine terminals and altered dopamine release and uptake in parkinsonian dyskinaesia. Brain, 131, 1574-1587.
39. Perovic, M., Mladenovic, A., Rakic, L., Ruzdijic, S. and Kanazir, S. (2005) Increase of GAP-43 in the rat cerebellum following unilateral striatal 6-OHDA lesion. Synapse, 56, 170-174.
40. Yamamoto, N., Sawada, H., Izumi, Y., Kume, T., Katsuki, H., Shimohama, S. and Akaike, A. (2007) Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease. J. Biol. Chem., 282, 4364-4372.
41. Ghee, M., Fournier, A. and Mallet, J. (2000) Rat alpha-synuclein interacts with Tat binding protein 1, a component of the 26S proteasomal complex. J. Neurochem., 75, 2221-2224.
42. Marx, F.P., Soehn, A.S., Berg, D., Melle, C., Schiesling, C., Lang, M., Kautzmann, S., Strauss, K.M., Franck, T., Engelender, S. et al. (2007) The proteasomal subunit S6 ATPase is a novel synphilin-1 interacting protein-implications for Parkinson's disease. FASEB J., 21, 1759-1767.
43. Bukhatwa, S., Zeng, B.Y., Rose, S. and Jenner, P. (2010) A comparison of changes in proteasomal subunit expression in the Substantia nigra in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Brain Res., 1326, 174-183.
44. Schell, H., Hasegawa, T., Neumann, M. and Kahle, P.J. (2009) Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice. Neuroscience, 160, 796-804.
45. Chau, K.Y., Ching, H.L., Schapira, A.H. and Cooper, J.M. (2009) Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson's disease pathogenesis. J. Neurochem., 110, 1005-1013.
46. Sanchez-Guajardo, V., Febbraro, F., Kirik, D. and Romero-Ramos, M. (2010) Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS ONE, 5, e8784.
47. Racchetti, G., D'Alessandro, R. and Meldolesi, J. (2012) Astrocyte stellation, a process dependent on Rac1 is sustained by the regulated exocytosis of enlargeosomes. Glia, 60, 465-475.
48. Lee, H.J., Suk, J.E., Patrick, C., Bae, E.J., Cho, J.H., Rho, S., Hwang, D., Masliah, E. and Lee, S.J. (2010) Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J. Biol. Chem., 285, 9262-9272.
49. Grommes, C., Lee, C.Y., Wilkinson, B.L., Jiang, Q., Koenigsknecht-Talboo, J.L., Varnum, B. and Landreth, G.E. (2008) Regulation of microglial phagocytosis and inflammatory gene expression by Gas6 acting on the Axl/Mer family of tyrosine kinases. J. Neuroimmune Pharmacol., 3, 130-140.
50. McNaught, K.S., Belizaire, R., Isacson, O., Jenner, P. and Olanow, C.W. (2003) Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol., 179, 38-46.
51. Nakamura, A., Kitami, T., Mori, H., Mizuno, Y. and Hattori, N. (2006) Nuclear localization of the 20S proteasome subunit in Parkinson's disease. Neurosci. Lett., 406, 43-48.
52. McNaught, K.S., Jnobaptiste, R., Jackson, T. and Jengelley, T.A. (2010) The pattern of neuronal loss and survival may reflect differential expression of proteasome activators in Parkinson's disease. Synapse, 64, 241-250.
53. Hu, R., Xu, C., Shen, G., Jain, M.R., Khor, T.O., Gopalkrishnan, A., Lin, W., Reddy, B., Chan, J.Y. and Kong, A.N. (2006) Identification of Nrf2-regulated genes induced by chemopreventive isothiocyanate PEITC by oligonucleotide microarray. Life Sci., 79, 1944-1955.
54. Hu, R., Xu, C., Shen, G., Jain, M.R., Khor, T.O., Gopalkrishnan, A., Lin, W., Reddy, B., Chan, J.Y. and Kong, A.N. (2006) Gene expression profiles induced by cancer chemopreventive isothiocyanate sulforaphane in the liver of C57BL/6J mice and C57BL/6J/Nrf2 (-/-) mice. Cancer Lett., 243, 170-192.
55. Braak, H., Sastre, M. and Del Tredici, K. (2007) Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease. Acta Neuropathol., 114, 231-241.
56. Terada, S., Ishizu, H., Yokota, O., Tsuchiya, K., Nakashima, H., Ishihara, T., Fujita, D., Ueda, K., Ikeda, K. and Kuroda, S. (2003) Glial involvement in diffuse Lewy body disease. Acta Neuropathol., 105, 163-169.
57. Park, J.Y., Paik, S.R., Jou, I. and Park, S.M. (2008) Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: implications for Parkinson's disease. Glia, 56, 1215-1223.
58. Suganuma, H., Fahey, J.W., Bryan, K.E., Healy, Z.R. and Talalay, P. (2011) Stimulation of phagocytosis by sulforaphane. Biochem. Biophys. Res. Commun., 405, 146-151.
59. Binder, M.D. and Kilpatrick, T.J. (2009) TAM receptor signalling and demyelination. Neurosignals, 17, 277-287.
60. Zhang, W., Dallas, S., Zhang, D., Guo, J.P., Pang, H., Wilson, B., Miller, D.S., Chen, B., McGeer, P.L., Hong, J.S. et al. (2007) Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. Glia, 55, 1178-1188.
61. Innamorato, N.G., Jazwa, A., Rojo, A.I., Garcia, C., Fernandez-Ruiz, J., Grochot-Przeczek, A., Stachurska, A., Jozkowicz, A., Dulak, J. and Cuadrado, A. (2010) Different susceptibility to the Parkinson's toxin MPTP in mice lacking the redox master regulator Nrf2 or its target gene heme oxygenase-1. PLoS ONE, 5, e11838.
62. Schipper, H.M., Liberman, A. and Stopa, E.G. (1998) Neural heme oxygenase-1 expression in idiopathic Parkinson's disease. Exp. Neurol., 150, 60-68.
63. Sykiotis, G.P. and Bohmann, D. (2010) Stress-activated cap'n'collar transcription factors in aging and human disease. Sci. Signal., 3, re3.
64. Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I. et al. (1997) An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun., 236, 313-322.
65. Paxinos, G. and Franklin, K.B.J. (2004) The mouse brain in stereotaxic coordinates. Elsevier Academic Press, Amsterdam, the Netherlands.
66. West, M.J., Slomianka, L. and Gundersen, H.J. (1991) Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat. Rec., 231, 482-497.
67. Schmitz, C. and Hof, P.R. (2007) Design-based stereology in brain aging research. In Riddle, D.R. (eds), Brain Aging: Models, Methods, and Mechanisms. CRC Press, Boca Raton, FL.
68. Gundersen, H.J. and Jensen, E.B. (1987) The efficiency of systematic sampling in stereology and its prediction. J. Microsc., 147, 229-263.